 |
ACADIA Pharmaceuticals
ACAD
|
37.5 |
$ 22.56 |
2.13 % |
$ 3.74 B |
USA |
 |
Acorda Therapeutics
ACOR
|
48.3 |
- |
-24.86 % |
$ 820 K |
USA |
 |
Adverum Biotechnologies
ADVM
|
222 |
- |
- |
$ 86.2 M |
USA |
 |
I-Mab
IMAB
|
271 |
- |
- |
$ 866 M |
China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 |
- |
- |
$ 40.3 B |
USA |
 |
Akebia Therapeutics
AKBA
|
62.9 |
$ 1.43 |
3.62 % |
$ 368 M |
USA |
 |
Midatech Pharma plc
MTP
|
204 |
- |
-18.52 % |
$ 27.3 M |
Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K |
- |
-1.52 % |
$ 24.7 M |
USA |
 |
Alnylam Pharmaceuticals
ALNY
|
58.1 |
$ 327.25 |
2.42 % |
$ 42.9 B |
USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K |
$ 3.9 |
3.7 % |
$ 9.38 B |
Australia |
 |
Autolus Therapeutics plc
AUTL
|
58.2 |
$ 1.49 |
9.56 % |
$ 397 M |
Britain |
 |
Advaxis
ADXS
|
88.1 |
- |
-9.65 % |
$ 45.9 M |
USA |
 |
Amphastar Pharmaceuticals
AMPH
|
70.9 |
$ 20.4 |
-0.87 % |
$ 954 M |
USA |
 |
Aquestive Therapeutics
AQST
|
103 |
$ 4.18 |
1.21 % |
$ 447 M |
USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 |
- |
- |
$ 7.46 M |
Israel |
 |
Aytu BioScience
AYTU
|
150 |
$ 2.66 |
3.5 % |
$ 16.7 M |
USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 |
$ 24.61 |
5.76 % |
$ 3.13 B |
USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 |
- |
0.49 % |
$ 251 B |
Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
146 |
- |
5.93 % |
$ 314 M |
Canada |
 |
AgeX Therapeutics
AGE
|
186 |
- |
-10.17 % |
$ 12.2 K |
USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 |
- |
- |
$ 1.01 B |
USA |
 |
CymaBay Therapeutics
CBAY
|
182 |
- |
- |
$ 3.45 B |
USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 |
- |
- |
$ 26.5 M |
USA |
 |
Avid Bioservices
CDMO
|
45.6 |
- |
- |
$ 789 M |
USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K |
- |
- |
$ 1.41 B |
USA |
 |
AIkido Pharma
AIKI
|
17.9 |
- |
1.93 % |
$ 17.4 M |
USA |
 |
Checkpoint Therapeutics
CKPT
|
6.83 |
- |
- |
$ 169 M |
USA |
 |
Celldex Therapeutics
CLDX
|
321 |
$ 32.41 |
3.38 % |
$ 2.15 B |
USA |
 |
Celsion Corporation
CLSN
|
15.6 |
- |
-6.63 % |
$ 13.9 M |
USA |
 |
CureVac N.V.
CVAC
|
13.6 |
- |
- |
$ 867 M |
Germany |
 |
Chimerix
CMRX
|
588 |
- |
- |
$ 756 M |
USA |
 |
Concert Pharmaceuticals
CNCE
|
147 |
- |
- |
$ 401 M |
USA |